An observational study in Gestational Diabetes, Cardiovascular Diseases and Placenta Diseases, sponsored by Oslo University Hospital. Not yet recruiting at 1 site in Norway. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-23.
Sponsored by Oslo University Hospital · Observational
The GaP study is designed to close important knowledge gaps by:
The incidence of gestational diabetes mellitus (GDM) is increasing. GDM has potential adverse short and long term health effects for both the women and her offspring, and involves dysfunctional interaction between placenta and the maternal body. The burden for the individual, the health system and society warrants further investigations into the placental-maternal crosstalk in GDM in order to improve personalized pregnancy surveillance and follow-up. In Oslo county, nearly twice as many women who give birth suffer from GDM (5.7%) than from preeclampsia (2.3%). The large obstetric department at Ullevål provides an optimal environment for novel translational studies and clinical practical aspects of GDM. The GaP study is designed to close important knowledge gaps by:
Pregnant women with GDM (diagnosed according to guidelines and referred to our outpatient clinic) and healthy, euglycemic pregnant women (Control group: referred for breech evaluation, planning of elective cesarean section, suspected reduced or increased fetal growth with a normal finding at ultrasound). Patients can be recruited from outpatient clinic, prior to induction, at admission for elective cesaerean section or at admission for labor (but not yet in active labor)
Exclusion Criteria:
Any treatment. N=200.
Gestational-age matched, euglycemic, normotensive pregnant women (n=150)
Number of women with altered levels of circulating senescence markers
Levels of maternal circulating senescence markers, e.g. SAA1, free thiol and related markers, in case group compared to controls
Time frame: 4 years
Number of women with altered levels of tissue-based senescence markers
Expression of markers of senescence in placental tissue, as assesed by immunohistochemistry (e.g. IL-6, p21, p16 and related markers) in case group compared to controls
Time frame: 4 years
Number of women with increased values for postpartum surrogate markers for impaired cardiovascular function
As assessed by circulating maternal levels of cardiovascular biomarkers, e.g. HDL (mmol/l), LDL (mmol/l) and related markers in case group compared to controls
Time frame: 4 years
Number of women with increased values for postpartum surrogate markers for impaired cardiovascular function
As assessed by circulating maternal levels of cardiovascular biomarkers, e.g. GDF-15 (ng/l), NT-pro BNP (ng/l), Troponin (ng/l) and related markers in case group compared to controls
Time frame: 4 years
Number of neonates with adverse neonatal outcome
A composite measure for neonatal outcome will be created using information on fetal acidemia, Apgar-score, asphyxia, intra-/postpartum fetal death, neonatal intubation/mechanical ventilation, meconium aspiration syndrome, netonatal hypoxic-ishcemic encephalopathy, therapeutic hypothermia of the neonate, rate of acute cesarean section (due to suspected fetal distress) and compared in case group and controls
Time frame: 4 years
Number of participants with operative vaginal delivery due to suspected fetal distress
Rates of operative vaginal deliveries (forceps/vacuum/combined; due to suspected fetal distress) in case and control groups
Time frame: 4 years
Percentage of participants with pathological placenta histology findings in case and control groups
As assessed by a senior perinatal pathologist using predefined criteria
Time frame: 4 years
Plan to share: Undecided — Depending on when the permission for the dataset usage for the project's outcome measures ends (OUH personal data officer/Regional Ethical Comittee) AND Norwegian legislation regarding personal data protection. It is unlikely that a major part of the data set will be shared openly due to these restrictions on sensitive personal data matters.
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oslo University Hospital